Boehringer Ingelheim Acquires GST

Boehringer Ingelheim

Boehringer Ingelheim, an Ingelheim, Germany-based market leader in animal health, acquired Global Stem cell Technology (GST), a Belgian veterinary biotech company.

The amount of the deal was not disclosed.

Led by Jan Spaas, CEO, GST is dedicated to the research, development and production of evidence-based, regenerative medicines (stem cell therapies) used to treat orthopedic and metabolic diseases in animals.

Boehringer Ingelheim already entered into a partnership with GST in 2018; in 2019, the companies launched Arti-Cell® Forte in Europe.

Arti-Cell® Forte is a stem cell product in the veterinary world granted marketing authorization by the European Commission. The acquisition and integration of GST will accelerate the development pipeline of Boehringer Ingelheim.



Join the discussion